These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7850293)

  • 41. Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer.
    Ryan CJ; Zelefsky MJ; Heller G; Regan K; Leibel SA; Scher HI; Kelly WK
    Urology; 2004 Jul; 64(1):90-4. PubMed ID: 15245942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
    Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 44. External beam radiotherapy for carcinoma of the prostate: a retrospective study.
    Mithal NP; Hoskin PJ
    Clin Oncol (R Coll Radiol); 1993; 5(5):297-301. PubMed ID: 8305338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
    Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
    Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
    BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improved local control and survival for surgically staged patients with locally advanced prostate cancer treated with up-front low dose rate iridium-192 prostate implantation and external beam irradiation.
    Stromberg J; Martinez A; Benson R; Garton G; Diokno A; Gonzalez J; Zincke H; Schray M; Edmundson G; Brabbins D
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):67-75. PubMed ID: 8270460
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma.
    Sumi M; Ikeda H; Tokuuye K; Kagami Y; Murayama S; Tobisu K; Kakizoe T
    Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):519-28. PubMed ID: 10974471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biologic classification as an alternative to anatomic staging for clinically localized prostate cancer: a proposal based on patients treated with external beam radiotherapy.
    Ennis RD; Malyszko BK; Rescigno J; Whitman AE; Heitjan DF; O'Toole KM; Rubin M; Schiff PB
    Urology; 1998 Feb; 51(2):265-70. PubMed ID: 9495709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
    Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
    J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
    Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
    Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of pelvic recurrence and distant metastasis in prostate carcinoma following definitive radiotherapy.
    Lai PP; Perez CA; Lockett MA
    Int J Radiat Oncol Biol Phys; 1992; 24(3):423-30. PubMed ID: 1399726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control.
    Syndikus I; Pickles T; Kostashuk E; Sullivan LD
    J Urol; 1996 Jun; 155(6):1983-6. PubMed ID: 8618303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential benefit of improved local tumor control in patients with prostate carcinoma.
    Kuban DA; el-Mahdi AM; Schellhammer PF
    Cancer; 1995 May; 75(9):2373-82. PubMed ID: 7536125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
    Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
    Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Matched-cohort analysis of patients with prostate cancer followed with observation or treated with three-dimensional conformal radiation therapy.
    Kramer NM; Horwitz EM; Uzzo RG; Hanlon AL; Hanks GE
    BJU Int; 2004 Jul; 94(1):59-62. PubMed ID: 15217432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.